Chai Discovery’s $130m bet: can “CAD for molecules” make biologics faster and cheaper?
With a $130m Series B, the startup is betting that
From Cow-Free Dairy to Human Milk 2.0: Biotechs Race to Brew Breast Milk Proteins
The first wave of “milk without cows” promised more sustainable
When the FDA Starts Trusting Algorithms: What AIM-NASH Means for Liver Drug Trials
Regulators have just qualified an AI system to score liver
The anti-ageing bet on the liver: why longevity biotech’s first real drugs may start here
A new generation of biotech start-ups is trying to “rejuvenate”
From California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome Care
When a three-year-old from California flies to Manchester for a
A pill to live to 150? China’s grapeseed longevity hype gets right — and wrong
Lonvi Biosciences says its procyanidin C1 capsule could, one day,
A one-time gene edit for cholesterol: promise, price and the risks we can’t yet see
Early data from a tiny trial suggest that a single
The explainable aging clock regulators might actually like
A new bioRxiv preprint introduces ACE—Aging Cell Embeddings—an explainable, deep-generative
The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger
As the GLP-1 gold rush enters its most aggressive phase,
Intellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pause
Standfirst: A hospitalised patient with a Hy’s-law-like profile has forced
Galapagos quits cell therapy. Europe’s CGT reckoning begins.
Late on Monday night in California — 10:30 p.m. PT
The AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotech
Lila’s Nvidia-backed raise is about more than money. It is
AstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equity
AstraZeneca has inked a deal worth “up to” $555 million
Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?
Pfizer has rejoined the weight-loss race with a $4.9bn move
Dermatology’s next play: bispecifics that shut down OX40L and TNF
Pairing a T-cell co-stimulatory brake with an inflammatory workhorse is
Base & Prime Editing Move from Hype to Timelines: What Hits Patients 2026–2030?
Beyond CRISPR Hype Gene editing has promised to revolutionize medicine,
The hypertension reset: a daily aldosterone blocker meets a twice-yearly gene-silencer
Madrid has put blood pressure back on the biotech map.
The patch that could unstick vaccination: Vaxxas’s A$90m bet on needle-free delivery
Brisbane-based Vaxxas has raised ~A$90m (A$49.22m Series D equity plus
From Hope to Proof: How Prasad’s FDA Could Reshape Biotech Approvals
When Dr. Vinay Prasad was abruptly removed from his FDA
From Platform to Precision: The $800M Bet Transforming Biotech Investing
Inside TCG Labs Soleil’s $400M Bet on Focused Biotech On
More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech
In the high-stakes world of biotechnology, big pharma acquisitions often
EU’s €12.5M Bet on Oncomatryx and Antibody-Drug Conjugates (ADCs)
European biotech received a confidence boost as the EU’s European
Gene Editing for Everyone: CRISPRware and the Open-Source Biotech Revolution
CRISPRware Signals a New Era in Democratized Gene Editing In
Texas Ban on Lab-Grown Meat Triggers Policy and Legal Showdowns
A State-Level Ban in the Lone Star State In a
